SG11201502816YA - Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics - Google Patents

Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Info

Publication number
SG11201502816YA
SG11201502816YA SG11201502816YA SG11201502816YA SG11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA
Authority
SG
Singapore
Prior art keywords
production
recombinant antibody
signal peptides
antibody therapeutics
heavy chain
Prior art date
Application number
SG11201502816YA
Inventor
Zhiwei Song
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201502816YA priority Critical patent/SG11201502816YA/en
Publication of SG11201502816YA publication Critical patent/SG11201502816YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
SG11201502816YA 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics SG11201502816YA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201502816YA SG11201502816YA (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2012076295 2012-10-12
SG11201502816YA SG11201502816YA (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
PCT/SG2013/000360 WO2014058389A1 (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Publications (1)

Publication Number Publication Date
SG11201502816YA true SG11201502816YA (en) 2015-05-28

Family

ID=50477711

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502816YA SG11201502816YA (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Country Status (5)

Country Link
US (1) US10066019B2 (en)
EP (1) EP2906599B1 (en)
CN (1) CN104854133B (en)
SG (1) SG11201502816YA (en)
WO (1) WO2014058389A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854133B (en) 2012-10-12 2018-10-30 新加坡科技研究局 It is used to prepare the best heavy chain and light chain signal peptide of recombinant antibodies therapeutic agent
KR102092225B1 (en) 2014-04-30 2020-03-23 주식회사 엘지화학 A protein secretory factor with a high secretory efficiency and a expression vector comprising the same
CN105820246A (en) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 Method for preparing novel recombinant anti-TNF alpha chimeric monoclonal antibody and application thereof
US10830780B2 (en) * 2015-01-26 2020-11-10 Biotech Institute, Llc Apparatus and methods for sample analysis and classification based on terpenes and cannabinoids in the sample
AU2016210918A1 (en) * 2015-01-28 2017-07-13 Pfizer Inc., Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
UY37269A (en) 2016-06-02 2018-01-02 Abbvie Inc GLUCOCORTICOID AND IMMUNOCONJUGATE RECEPTOR AGONIST OF THE SAME
EA201892653A1 (en) * 2016-06-30 2019-05-31 Селлтрион Инк. STABLE LIQUID PHARMACEUTICAL COMPOSITION
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
WO2019055471A1 (en) * 2017-09-18 2019-03-21 Amyris, Inc. Methods for producing full-length antibodies
CN107488636A (en) * 2017-09-30 2017-12-19 山东兴瑞生物科技有限公司 A kind of immunocyte of anti-HER2 Chimeric antigen receptors modification for carrying molecular switch and its application
PL3658192T3 (en) 2017-12-01 2021-10-18 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP7072792B2 (en) * 2017-12-11 2022-05-23 国立大学法人神戸大学 Bispecific antibody
US11447547B1 (en) * 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
CN108103088B (en) * 2017-12-21 2021-03-26 广东东阳光药业有限公司 Optimized gene of recombinant GLP-1 analogue Fc fusion protein and application thereof
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
WO2020229621A1 (en) * 2019-05-15 2020-11-19 Kymab Limited Improved lambda antibodies
CN111072764A (en) * 2019-12-13 2020-04-28 东莞市东阳光生物药研发有限公司 Preparation method of recombinant human Activin A
SE543998C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Dna construct for expressing nivolumab
SE544006C2 (en) * 2020-03-17 2021-11-02 Xbrane Biopharma Ab Novel combination of tis sequence and signal peptide sequence for expressing a recombinant protein
SE543999C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Dna construct for expressing a novel signal peptide
CA3171532A1 (en) * 2020-03-17 2021-09-23 Kiavash MIRZADEH Novel combination of tis sequence and signal peptide sequence for expressing a recombinant protein
KR102457344B1 (en) * 2020-06-22 2022-10-24 건국대학교 글로컬산학협력단 Antigen binding fragment platform conjugated with anticancer peptides
TW202227482A (en) * 2020-08-28 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Signal peptide for reducing terminal heterogeneity of heterologous polypeptide
CN112979782B (en) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 Polypeptide and application thereof
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023081733A1 (en) * 2021-11-02 2023-05-11 Washington University Compositions and methods of treatment for cancers
WO2023220118A2 (en) * 2022-05-10 2023-11-16 Regenerative Research Foundation Compositions and methods for controlled protein degradation in neurodegenerative disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506132A (en) 1993-07-28 1996-04-09 Sandoz Pharmaceuticals Corporation Human antibodies against varicella-zoster virus
PT1527100E (en) 2002-03-29 2009-08-25 Schering Corp Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
WO2004031362A2 (en) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
PT1648998E (en) * 2003-07-18 2014-11-04 Amgen Inc Specific binding agents to hepatocyte growth factor
CN101292036B (en) * 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 For the method for recombinant expressed polypeptide
WO2008100563A2 (en) 2007-02-14 2008-08-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
EP2493923A1 (en) * 2009-10-30 2012-09-05 Abbott Laboratories Sorf constructs and multiple gene expression
CN104854133B (en) 2012-10-12 2018-10-30 新加坡科技研究局 It is used to prepare the best heavy chain and light chain signal peptide of recombinant antibodies therapeutic agent

Also Published As

Publication number Publication date
US10066019B2 (en) 2018-09-04
EP2906599A1 (en) 2015-08-19
EP2906599B1 (en) 2019-07-17
EP2906599A4 (en) 2016-04-27
CN104854133A (en) 2015-08-19
CN104854133B (en) 2018-10-30
US20150225482A1 (en) 2015-08-13
WO2014058389A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
SG11201502816YA (en) Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
IL287270A (en) Anti-psgl-1 antibodies and uses thereof
IL292121A (en) Anti-plasma kallikrein antibodies
HK1206636A1 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
HK1210027A1 (en) Anti-human b7-h4 antibodies and their uses b7-h4
IL230918A0 (en) Modified proteins and peptides
HK1201296A1 (en) Modified fc region of antibody fc
IL224441B (en) Antibodies with modified isoelectric points
EP2904093A4 (en) Methods of quantitating heavy and light chain polypeptide pairs
HK1215446A1 (en) Anti-vegf antibodies and their uses vegf
EP2832855A4 (en) Novel anti-siglec-15 antibody
AP2013007135A0 (en) Anti-sclerostin antibody crystals and formulationsthereof
HK1208810A1 (en) C-terminal and central epitope a-beta antibodies c a-
EP2726103A4 (en) Anti-properdin antibodies and uses thereof
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
HK1222871A1 (en) Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
HK1220492A1 (en) Recombinant polypeptide production
EP2678440A4 (en) Yeast strain for the production of proteins with modified o-glycosylation
IL234394A0 (en) Recombinant antibodies with dual specifity for ganagliosides and their use
EP2688913A4 (en) High level production of recombinant proteins
EP2771689A4 (en) Usp2a peptides and antibodies
EP2726614A4 (en) Improving the production of foreign proteins
IL266073B (en) Heterodimeric antibody fccontaining proteins and methods for production thereof
HK1211952A1 (en) Recombinant protein
GB201121233D0 (en) Modified proteins and peptides